We are live on ! Find out more
NC

Nexthera Capital Portfolio holdings

AUM $120M
1-Year Est. Return 10.01%
This Fund
S&P 500
This Quarter Est. Return
+8.93%
1 Year Est. Return
+10.01%
3 Year Est. Return
+160.68%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$115M
AUM Growth
+$18.9M
Cap. Flow
+$18M
Cap. Flow %
15.6%
Top 10 Hldgs %
77.08%
Holding
48
New
17
Increased
12
Reduced
3
Closed
13

Top Buys

Rank Stock Value
1
GSK icon
GSK
GSK
+$19.8M
2
PFE icon
Pfizer
PFE
+$6.41M
3
AMGN icon
Amgen
AMGN
+$4.66M
4
NGNE icon
Neurogene
NGNE
+$3.96M
5
XLRN
Acceleron Pharma
XLRN
+$3.22M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$13.5M
2
AGN
Allergan plc
AGN
+$7.37M
3
BMY icon
Bristol-Myers Squibb
BMY
+$6.45M
4
SNY icon
Sanofi
SNY
+$4.7M
5
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$3.65M

Sector Composition

Rank Sector Weight
1 Healthcare 89.72%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
QURE icon
26
uniQure
QURE
$2.68B
$688K 0.6%
93,400
-21,600
-19% -$258K
SCYX icon
27
SCYNEXIS
SCYX
$37M
$597K 0.52%
+3,438
New +$973K
VTGN icon
28
VistaGen Therapeutics
VTGN
$9.29M
$539K 0.47%
+4,604
New +$528K
AVEO
29
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$498K 0.43%
+51,813
New +$500K
VSTM icon
30
Verastem
VSTM
$532M
$437K 0.38%
+28,000
New +$493K
IMGN
31
DELISTED
Immunogen Inc
IMGN
$433K 0.37%
140,500
-87,500
-38% -$549K
PGNX
32
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$405K 0.35%
96,000
– –
ZYNE
33
DELISTED
Zynerba Pharmaceuticals, Inc
ZYNE
$391K 0.34%
+57,100
New +$478K
EIGR
34
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$277K 0.24%
+467
New +$284K
ABEO icon
35
Abeona Therapeutics
ABEO
$345M
$236K 0.2%
+4,000
New +$273K
BMY icon
36
Bristol-Myers Squibb
BMY
$127B
– –
-101,000
Closed -$6.45M
IOVA icon
37
Iovance Biotherapeutics
IOVA
$2.23B
– –
-152,266
Closed -$774K
NBIX icon
38
Neurocrine Biosciences
NBIX
$17.7B
– –
-42,000
Closed -$1.66M
SNY icon
39
Sanofi
SNY
$104B
– –
-117,000
Closed -$4.7M
EGRX
40
PUT
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
– –
-33,000
Closed -$1.34M
INFI
41
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
– –
-145,000
Closed -$764K
TMBR
42
DELISTED
Timber Pharmaceuticals, Inc.
TMBR
– –
-23
Closed -$377K
FPRX
43
DELISTED
Five Prime Therapeutics, Inc.
FPRX
– –
-20,000
Closed -$813K
AGN
44
DELISTED
Allergan plc
AGN
– –
-27,500
Closed -$7.37M
HZNP
45
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
– –
-220,000
Closed -$3.65M
XNPT
46
DELISTED
XENOPORT, INC.
XNPT
– –
-80,000
Closed -$361K
CELG
47
DELISTED
Celgene Corp
CELG
– –
-135,000
Closed -$13.5M
NDRM
48
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
– –
-70,000
Closed -$988K
1
2

Similar funds

KAM
Kavi Asset Management New York $121M AUM 7.54% 1-Year Est. Return
VCP
Vernier Capital Partners New York $132M AUM 20.75% 1-Year Est. Return
PFC
Personal Financial Consultants Lafayette, California $133M AUM 5.06% 1-Year Est. Return
FCA
Florence Capital Advisors New York $105M AUM
TA
TMD & Associates Scottsdale, Arizona $146M AUM 1.29% 1-Year Est. Return
EBIM
Eagle Boston Investment Management Boston, Massachusetts $87.3M AUM 4.18% 1-Year Est. Return
BCM
BBT Capital Management Fort Worth, Texas $85.5M AUM 11.09% 1-Year Est. Return
ACP
ArcLight Capital Partners Boston, Massachusetts $83.2M AUM 32.11% 1-Year Est. Return

Nexthera Capital's Q2 2016 Portfolio in Review

As of Q2 2016, Nexthera Capital held 48 positions worth $115M, up 20% from $96.5M the previous quarter. Its ten largest holdings account for 77% of the portfolio.

Nexthera Capital deployed $18M of net new capital in Q2 2016, opening 17 new positions and adding to 12 existing holdings. Its largest new stake was GSK: 376,000 shares worth $20.4M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 90% a quarter earlier.

On the sell side, the largest reduction was Immunogen Inc, an estimated $549K trimmed.

  • Nexthera Capital's largest Q2 2016 buy was GSK: 376,000 shares worth $20.4M.
  • Nexthera Capital added most to Pfizer in Q2 2016, an estimated $6.41M increase.
  • Nexthera Capital's biggest Q2 2016 reduction was Immunogen Inc, cutting an estimated $549K.
  • Nexthera Capital fully exited Celgene Corp in Q2 2016, selling an estimated $13.5M.
  • Nexthera Capital's ten largest holdings make up 77% of its $115M portfolio in Q2 2016.
  • Nexthera Capital opened 17 new positions and closed 13 in Q2 2016.
  • Nexthera Capital's portfolio value rose 20% quarter-over-quarter to $115M.

Based on Nexthera Capital's 13F filing for Q2 2016, filed 15 Aug 2016.